“Roche Partners with China's Defand Therapeutics on Molecular Glue Drug Discovery” — what this page in the network covers. Roche has entered a drug discovery collaboration with Chinese biotech Defand Therapeutics, focusing on molecular glue medicines—a promising class of small molecules that induce targeted protein degradation. The deal underscores Roche's strategic push into novel modalities and its willingness to tap into China's rapidly advancing biotech ecosystem. While financial terms were not disclosed, such partnerships often include upfront payments, milestones, and royalties. Molecular glues work by facilitating interactions between disease-causing proteins and E3 ligases, leading to their degradation via the cell's natural disposal system.
This approach could address targets previously considered undruggable, offering new hope for cancer, neurological, and inflammatory diseases. For Defand, the collaboration provides validation and resources to advance its platform. The move reflects a broader industry trend of large pharma companies seeking external innovation in protein degradation, a field that has attracted significant investment. This listing links straight to the original page, where the content is available in full.